This week’s news from the life sciences includes Eli Lilly's investment in a Cambridge-Singapore biotech, Stealth ...

RNA specialist Wave Life Sciences has been told by Takeda that the Japanese drugmaker is to bring to an end the last facet of ...

Takeda Pharmaceutical offers a strong cash position and an above-average dividend yield. Find out why I'm bullish on TAK ...

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the ...

Takeda is walking away from the last target in a collaboration with Wave Life Scien | Takeda has brandished a termination ...

View Takeda Pharmaceutical Company Limited (TAK) current and estimated P/E ratio data provided by Seeking Alpha.

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other Japanese stocks. As we navigate through 2024, Japan’s economic ...

Pharmaceutical company Lupin has announced a non-exclusive patent licence agreement with Takeda Pharmaceutical for the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This company's current P/CF looks solid when ... but they help show that Takeda Pharmaceutical Co. Is likely being undervalued right now. Considering this, as well as the strength of its earnings ...

Last year, Takeda firmly cemented its place in the emerging markets when it acquired Swiss pharma company, Nycomed, for US $13.7bn. According to a recent report, Russia’s pharmaceutical market ...